HungaryHungary

Environmental Biotechnology R&D

05.02.2004

Kornél L. Kovács, Department of Biotechnology,
University of Szeged and Biological Research Center, Szeged
Environmental biotechnology plays an increasingly important role in the accession stage of the new EU member countries. Therefore the European Federation of Biotechnology has established one of its Regio-nal Branch Offices at the University of Sze-ged, where renewable energy production and bioremediation are in the focus of R&D.
Biohydrogen
Among the alternative energy carriers, hydrogen is preferred. Hydrogen can be produced in biological processes: solar energy captured by the photosynthetic apparatus is converted into chemical energy, oxygen and hydrogen can be produced. Upon utilization, these are combined to form water and energy is released in a cycle driven by the practically unlimited and safe energy of the sun. In addition to offering an alternative for the global energy crisis, biologically produced hydrogen may also serve as reductant for numerous microbiological activities of environmental significance. This principle has been employed in the complex microbiological series of events that leads to biogas formation. Biogas formation is intensified through the microbiological manipulation of the intermediate hydrogen production steps according to our patented procedure. The method has been tested in field experiments using agricultural and municipal organic wastes.
The understanding of molecular fundamentals of biohydrogen production and utilization among microbes is a goal of supreme importance both for basic and applied research applications. The key enzyme in biological hydrogen metabolism is hydrogenase, which catalyses the formation or decomposition of hydrogen. The simple-looking task is solved by a sophisticated molecular mechanism. Most hydrogenases are metalloenzymes, harbouring Ni and Fe atoms. Like most metalloenzymes, hydro-genases are extremely sensitive to inactivation by oxygen, high temperature, CO, CN, and other environmental factors. These properties are not favourable for the potential biotechnological applications.
A purple photosynthetic bacterium (Thiocapsa roseopersicina) contains hydro-genases, which display outstanding stability among enzymes possessing the same catalytic function. Understanding, through molecular biological studies, the physiological properties and the molecular factors that stabilize hydrogenases is expected to help design various enzymes equipped with resistance to the inactivating effect of high temperature, oxygen, and/or proteolytic attack for future biotechnological use. A genomic approach has been launched in order to understand the complex problem.
Hyperthermophiles and Methanotrophs
Hyperthermophilic micro-organisms grow above 80°C, and cannot proliferate below 70°C. By definition, enzymes operating in these unusual creatures are heat stable, therefore they offer an obvious advantage for biotechnological applications. In their chemolithotrophic mode of growth hydrogen metabolism plays a crucial role. We have developed a novel technique to plate hyper-thermophilic archaea. This is the first major step to study their microbiology, molecular biology and genetics.
Methanotrophic bacteria typically contain another metalloenzyme, methane mono-oxygenase (MMO). MMO can also attack several compounds representing serious environmental and public health hazard, such as chlorinated hydrocarbons. Methanotrophs are significant for practical utilization to produce alternative energy sources and environmental protection and remediation, improving the general quality of life.
Biodegradation of Xenobiotics
An important foreseeable task is the degradation of industrial and natural hazardous chemicals by the use of naturally occurring microbiological isolates. Because microorganisms can destroy the non-naturally occurring contaminants only slowly and hardly, it is a challenge to identify species that are able to survive and grow in this very unfavourable environment. Several microbiological degradation systems have been developed to efficiently bioremediate halogenated chemicals, sulfonated aromatic chemicals, keratin-containing waste of the food industry. Keratin is converted in a patented process efficiently to biohydrogen. A new fermentation facility is operated by the spin-off company Alfa-Bioner Ltd. to cultivate microbes for large scale bioremediation applications.
Contact
Prof. Dr. Kornél Kovács
Dep. of Biotechnology, University of Szeged
Tel./Fax: +36-62-544-351 / -352
eMail: Kornel@nucleus.szbk.u-szeged.hu
www.efbweb.org/rbo/szeged/htm

HungaryHungary

19.03.2008

Zagreb – Pliva d.d., Barr Pharmaceuticals‘ subsidiary in Croatia, is selling its three operations in Spain – Pliva Pharma Iberia, Laboratorios Edigen and Uso Racional – to Biomedica Foscama Industria Chimico-Farmaceutica. For a...

HungaryHungary

19.03.2008

Budapest – A Hungarian research consortium has been granted a 3-year fund of EUR2m by the Hungarian government to identify new enzyme targets against multi-restistant strains of the tuberculosis agent Mycobacterium tuberculosis...

HungaryHungary

19.02.2008

Debrecen – Israeli generic drugmaker Teva Pharmaceutical Industries is looking to expand its presence in Hungary. The pharma company wants to double capacity at its plant in Debrecen. This will involve a EUR70 million investment...

HungaryHungary

01.01.2008

Szeged – The development of inhibitors directed against matrix metalloproteinases is at the centre of a new funding project sponsored by the Hungarian National Office for Research and Technology (NKTH). The NKTH recently granted...

HungaryHungary

22.11.2007

Budapest/Mumbai – Solvo Biotechnology (Budapest) and Krishgen BioSystems (Mumbai, India) have formed a partnership to distribute and represent Solvo’s membrane transporter assay products and services in India. “Membrane...

HungaryHungary

24.09.2007

Sofia – Icelandic Actavis Group announced double-digit growth in Bulgaria in the first half of 2007. Sales were up 10,65% with more than €23.1 million and 24 new products launched in the first six months of 2007. “Actavis...

HungaryHungary

11.07.2007

Budapest – A new National Alliance for Rare Diseases in Hungary, termed Huferdis – Rare Diseases Hungary (Hungarian Federation of People with Rare and Congenital Diseases), was announced at the beginning of June. “The importance...

HungaryHungary

16.03.2007

Budapest – The EU Environment Council, made up of the European Ministers for the Environment, rejected the proposal in February from the European Commission to lift the Hungarian prohibition to grow genetically modified maize...

HungaryHungary

21.11.2006

Gödöllö – At the end of September, GlaxoSmithKline (GSK) inaugurated a new a100-million vaccine production plant 30 km northeast of the Hungarian capital.According to GSK, the new facility will be one of Europe’s most advanced...

HungaryHungary

21.07.2006

Sofia – On June 1 a law banning the production and sale of a range of genetically modified organisms (GMOs), including wheat, came into effect in Bulgaria. The law represents an about-face for the country, which has experimented...

Displaying results 21 to 30 out of 89

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-hungary/browse/2/article/environmental-biotechnology-rd.html

Image Gallery

Stock list

All quotes

TOP

  • GW PHARMACEUTICALS (UK)305.50 GBP39.3%
  • NEWRON (CH)15.60 CHF20.0%
  • TOPOTARGET (DK)3.52 DKK16.9%

FLOP

  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • WILEX (D)0.84 EUR-8.7%
  • GENFIT (F)22.42 EUR-8.1%

TOP

  • BIOTECH PHARMACON (N)18.80 NOK71.7%
  • WILEX (D)0.84 EUR47.4%
  • E-THERAPEUTICS (UK)27.75 GBP38.8%

FLOP

  • CYTOS (CH)0.17 CHF-93.8%
  • BIONOR PHARMA (N)2.11 NOK-47.3%
  • IMMUNICUM AB (S)16.60 SEK-36.2%

TOP

  • SILENCE THERAPEUTICS (UK)261.00 GBP6265.9%
  • IXICO (UK)68.00 GBP756.4%
  • PHARMING (NL)0.50 EUR733.3%

FLOP

  • CYTOS (CH)0.17 CHF-95.8%
  • EVOCUTIS (UK)0.22 GBP-91.8%
  • AGENNIX (D)0.04 EUR-77.8%

No liability assumed, Date: 23.04.2014

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

White Paper